EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)

Jaime Altcheh iD, Victor Sierra, Teresa Ramirez, Jimy José Pinto Rocha, Ulrike Grossmann, Erya Huang, Guillermo Moscatelli, Olivia Ding

Antimicrobial Agents and Chemotherapy · 18.04.2023 · 67 (4)

DOI: 10.1128/aac.01193-22 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.04.2023. Verfasst von Jaime Altcheh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Parasitología, Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA,…. Hauptthemen laut MEDLINE: Trypanocidal Agents, Chagas Disease, Nitroimidazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nifurtimox is recommended for the treatment of Chagas disease; however, long-term follow-up data are scarce. This prolonged follow-up phase of the prospective, historically controlled, CHICO clinical trial evaluated seronegative conversion in pediatric patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanocidal AgentsChagas DiseaseNitroimidazolesHumansChildAdolescentNifurtimoxFollow-Up StudiesProspective StudiesHistorically Controlled StudyTreatment OutcomeBody Weight

Stichwörter der Autor:innen

Chagas diseaseTrypanosoma cruzifollow-upnifurtimoxpediatricsseronegative conversiontreatment

Substanzen

NifurtimoxTrypanocidal AgentsNitroimidazoles

Autor:innen und Institutionen

  • Parasitología, Hospital de Niños Ricardo Gutiérrez and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP), CONICET-GCBA, Buenos Aires, Argentina.
  • Centro de Atención e Investigación Médica S.A., Yopal, Colombia.
  • Centro de Enfermedad de Chagas y Patologias Regionales, Santiago del Estero, Argentina.
  • Fundación CEADES-Plataforma de Atención Integral a los Pacientes con Enfermedades de Chagas, Cochabamba, Bolivia.
  • Bayer AG, Research and Development Pharmaceuticals, Berlin, Germany.
  • Bayer US LLC, Whippany, New Jersey, USA.

ORCID-Profile: Jaime Altcheh

Zitieren

APA

Altcheh, J., Sierra, V., Ramirez, T., Pinto Rocha, J. J., Grossmann, U., Huang, E., Moscatelli, G., & Ding, O. (2023). Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE). Antimicrobial Agents and Chemotherapy, 67(4). https://doi.org/10.1128/aac.01193-22

Vancouver

Altcheh J, Sierra V, Ramirez T, Pinto Rocha JJ, Grossmann U, Huang E, et al. Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE). Antimicrobial Agents and Chemotherapy. 2023;67(4). doi:10.1128/aac.01193-22

BibTeX
@article{Altcheh2023,
  author = {Altcheh, Jaime and Sierra, Victor and Ramirez, Teresa and Pinto Rocha, Jimy José and Grossmann, Ulrike and Huang, Erya and Moscatelli, Guillermo and Ding, Olivia},
  title = {Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {4},
  doi = {10.1128/aac.01193-22}
}
Kostenlos starten →